Biggest News Aggregation in the World
📰 Patrick Bursey News

Page 2 - Patrick Bursey News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Patrick Bursey. Real-time updates on events, politics, business and more.

Renovacor to Present at the 42nd Annual Cowen Health Care Conference

PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced that Magdalene Cook, M.D., Chief Exe...
United States John Mullaly Patrick Bursey Magdalene Cook Renovacor Inc Securities Exchange Commission

Renovacor to Participate in a Panel Presentation at the 11th Annual LifeSci Partners Corporate Acces

PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and related diseases, today announced that Magdalene Cook, M.D., President and Chief Execu...
United States John Mullaly Patrick Bursey Magdalene Cook Renovacor Inc Securities Exchange Commission

Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

For Trade and Medical Media Only Trial met FDA and EMA-pre-specified primary endpoints versus daily standard of care Data to support global regulatory filings in mid-2022 Cidara to host investor
United States San Diego Patrick Bursey Brian Sheehan Jan Milton Edwards George Thompson

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the Maintenance Treatment of Adults with Acromegaly

Message : Required fields NEEDHAM, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”) today presented patient-reported outcomes (PROs) data from its MPOWERED™ Phase 3 trial demonstrating that study patients with acromegaly reported significantly improved quality of life and work productivity after transitioning from long-acting injectable somatostatin analogs (iSSAs) to MYCAPSSA ®. The data were shared as an oral presentation at the 3...
United States Patrick Bursey William Ludlam Ashley Robinson Nienke Biermasz Lifesci Advisors

Chiasma to Present Encore and New Data from MPOWERED™ Phase

AACE -- -- e-ECE clinical data previously presented at Endocrine Society’s 2021 annual meeting -- NEEDHAM, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, today announced that it will virtually...
United States Patrick Bursey Murrayb Gordon Pamela Freda Ashley Robinson Anthonyp Heaney

Chiasma Reports First Quarter Financial Results and Announced Agreement to Merge with Amryt

Chiasma Reports First Quarter Financial Results and Announced Agreement to Merge with Amryt Announced agreement to merge with Amryt Combination to create a global commercial stage rare and orphan disease leader with a diversified portfolio of therapies and a meaningful late-stage development pipeline Q1 2021 Net Product Revenues of $1.9M, a 100% increase over Q4 2020 Achieved payor coverage of MYCAPSSA for over 185 million lives Submitted an Investigational New Drug (IND) application for the st...
United States Patrick Bursey Raj Kannan Ashley Robinson Amryt Pharma Lifesci Advisors

Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology Annual Meeting

Share: Secondary endpoint data for once-nightly FT218 further supports previously announced topline data demonstrating clinically meaningful results at 6 g, 7.5 g, and 9 g doses DUBLIN, Ireland, April 17, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate (ON-SXB) for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy, today announced the pre...
United States Jennifer Gudeman Tom Mchugh Patrick Bursey Avadel Micropump Michaelj Thorpy

Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium ... Avadel Pharmaceuticals plcApril 17, 2021 GMT Secondary endpoint data for once-nightly FT218 further supports previously announced topline data demonstrating clinically meaningful results at 6 g, 7.5 g, and 9 g doses DUBLIN, Ireland, April 17, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AV...
United States Jennifer Gudeman Tom Mchugh Patrick Bursey Avadel Micropump Michaelj Thorpy
Source: apnews.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science